精准医学与肝衰竭治疗策略

朱冰; 辛绍杰; 游绍莉

doi:10.3969/j.issn.1001-5256.2018.09.003

精准医学与肝衰竭治疗策略

DOI: 10.3969/j.issn.1001-5256.2018.09.003

解放军第三二医院肝衰竭诊疗与研究中心

基金项目:

北京市首都特色重点课题(Z151100004015019)；

详细信息

中图分类号: R575.3
计量
- 文章访问数: 2097
- HTML全文浏览量: 83
- PDF下载量: 373
- 被引次数: 0
出版历程
- 收稿日期: 2018-06-08
- 出版日期: 2018-09-20

Precision medicine and treatment strategies for liver failure

Liver Failure Treatment and Research Center, 302 Hospital of PLA

Research funding:

摘要

摘要: 肝衰竭是最严重的临床疾病类型之一,其临床救治成功率较低。精准医学概念的提出为肝衰竭治疗研究提供了更多启示。从准确认识精准医学的科学内涵,利用先进技术提高肝衰竭的精准诊断水平;寻找肝衰竭治疗新靶点,阻断肝细胞坏死;以及采用基因技术实现肝衰竭的精准用药与个体化生物治疗等方面进行了阐述,认为肝衰竭的精准诊断和治疗有利于提高其救治水平。
- 肝功能衰竭 /
- 诊断 /
- 治疗学 /
- 精准医学
Abstract: Liver failure is one of the most serious diseases in clinical practice and has a low treatment success rate. The concept of precision medicine provides more enlightenment for the treatment of liver failure. An accurate understanding of the scientific connotation of precision medicine and the application of advanced techniques can improve the accurate diagnosis of liver failure. This article elaborates on the search for new treatment targets, blockade of hepatocyte necrosis, and the application of genetic technology to realize accurate medication and individualized biotherapy for liver failure. It is pointed out that the accurate diagnosis and treatment of liver failure can improve the level of treatment.
- liver failure /
- diagnosis /
- therapeutics /
- precision medicine

HTML全文

参考文献(38)

[1]REUBEN A, TILLMAN H, FONTANA RJ, et al.Outcomes in adults with acute liver failure between 1998 and 2013:An observational cohort study[J].Ann Intern Med, 2016, 164 (11) :724-732.

[2]ZAMORA R, VODOVOTZ Y, MI Q, et al.Data-driven modeling for precision medicine in pediatric acute liver failure[J].Mol Med, 2016.[Epub ahead of print]

[3]KORTM F, MARQUARDT I, ALAWI M, et al.Acute liver failure meets SOPH syndrome:A case report on an intermediate phenotype[J].Pediatrics, 2017, 139 (1) :e20160550.

[4]ASHLEY EA.The precision medicine initiative:A new national effort[J].JAMA, 2015, 313 (21) :2119-2120.

[5]CHUN M.Precision medicine initiative in the offing[J].Cancer Discov, 2015, 5 (5) :456.

[6]COLLINS FS, VARMUS H.A new initiative on precision medicine[J].N Engl J Med, 2015, 372 (9) :793-795.

[7]NIMMESGERN E, BENEDIKTSSON I, NORSTEDT I.Personalized medicine in Europe[J].Clin Transl Sci, 2017, 10 (2) :61-63.

[8]NARKEWICZ MR, DELL OD, KARPEN SJ, et al.Pattern of diagnostic evaluation for the causes of pediatric acute liver failure:An opportunity for quality improvement[J].J Pediatr, 2009, 155 (6) :801-806.e1.

[9]LEE WM.Recent developments in acute liver failure[J].Best Pract Res Clin Gastroenterol, 2012, 26 (1) :3-16.

[10]OKETANI M, IDO A, NAKAYAMA N, et al.Etiology and prognosis of fulminant hepatitis and late-onset hepatic failure in Japan:Summary of the annual nationwide survey between 2004 and 2009[J].Hepatol Res, 2013, 43 (2) :97-105.

[11]YOU S, RONG Y, ZHU B, et al.Changing etiology of liver failure in 3, 916 patients from northern China:A 10-year survey[J].Hepatol Int, 2013, 7 (2) :714-720.

[12]YAMAMOTO T, TAJIMA Y.HMGB1 is a promising therapeutic target for acute liver failure[J].Expert Rev Gastroenterol Hepatol, 2017, 11 (7) :673-682.

[13]European Association for the Study of the Liver.EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis[J].J Hepatol, 2018.[Epub ahead of print]

[14]BERNAL W, WENDON J.Acute liver failure[J].N Engl J Med, 2013, 369 (26) :2525-2534.

[15]FAGAN EA.Acute liver failure of unknown pathogenesis:the hidden agenda[J].Hepatology, 1994, 19 (5) :1307-1312.

[16]STEPHENS MC, BOARDMAN LA, LAZARIDIS KN.Individualized medicine in gastroenterology and hepatology[J].Mayo Clin Proc, 2017, 92 (5) :810-825.

[17]FIX OK, LIOU I, KARVELLAS CJ, et al.Development and pilot of a checklist for management of acute liver failure in the intensive care unit[J].PLo S One, 2016, 11 (5) :e0155500.

[18]LEE WM, BROWN KE, YOUNG NS, et al.Brief report:No evidence for parvovirus B19 or hepatitis E virus as a cause of acute liver failure[J].Dig Dis Sci, 2006, 51 (10) :1712-1715.

[19]LEVITSKY J, DUDDEMPUDI AT, LAKEMAN FD, et al.Detection and diagnosis of herpes simplex virus infection in adults with acute liver failure[J].Liver Transpl, 2008, 14 (10) :1498-1504.

[20]MELLINGER JL, ROSSARO L, NAUGLER WE, et al.Epstein-Barr virus (EBV) related acute liver failure:A case series from the US A-cute Liver Failure Study Group[J].Dig Dis Sci, 2014, 59 (7) :1630-1637.

[21]STRAVITZ RT, KRAMER DJ.Management of acute liver failure[J].Nat Rev Gastroenterol Hepatol, 2009, 6 (9) :542-53.

[22]SOMASEKAR S, LEE D, RULE J, et al.Viral surveillance in serum samples from patients with acute liver failure by metagenomic next-generation sequencing[J].Clin Infect Dis, 2017, 65 (9) :1477-1485.

[23]LARSON AM, POLSON J, FONTANA RJ, et al.Acetaminophen-induced acute liver failure:Results of a United States multicenter, prospective study[J].Hepatology, 2005, 42 (6) :1364-1372.

[24]OSTAPOWICZ G, FONTANA RJ, SCHIDT FV, et al.Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States[J].Ann Intern Med, 2002, 137 (12) :947-954.

[25]FUJIWARA K, YASUI S, NAKANO M, et al.Severe and fulminant hepatitis of indeterminate etiology in a Japanese center[J].Hepatol Res, 2015, 45 (10) :e141-149.

[26]ALONSO EM, JAMES LP, ZHANG S, et al.Acetaminophen adducts detected in serum of pediatric patients with acute liver failure[J].J Pediatr Gastroenterol Nutr, 2015, 61 (1) :102-107.

[27]DAVERN TJ, JAMES LP, HINSON JA, et al.Measurement of serum acetaminophen-protein adducts in patients with acute liver failure[J].Gastroenterology, 2006, 130 (3) :687-694.

[28]WENDON J, CORDOBA J, DHAWAN A, et al.EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure[J].J Hepatol, 2017, 66 (5) :1047-1081.

[29]HEGARTY R, HADZIC N, GISSEN P, et al.Inherited metabolic disorders presenting as acute liver failure in newborns and young children:King's College Hospital experience[J].Eur J Pediatr, 2015, 174 (10) :1387-1392.

[30]STAUFNER C, HAACK TB, KPKE MG, et al.Recurrent acute liver failure due to NBAS deficiency:Phenotypic spectrum, disease mechanisms, and therapeutic concepts[J].J Inherit Metab Dis, 2016, 39 (1) :3-16.

[31]BERNSMEIER C, ANTONIADES CG, WENDON J.What's new in acute liver failure[J].Intensive Care Med, 2014, 40 (10) :1545-1548.

[32]MAHFOUDH BA, SELMI R, BEJAOUI M, et al.Effectiveness of a single versus repeated administration of trimetazidine in the protection against warm ischemia/reperfusion injury of rat liver[J].Turk J Med Sci, 2016, 46 (4) :1258-1264.

[33]CHEN H, SHEN ZY, XU W, et al.Expression of P450 and nuclear receptors in normal and end-stage Chinese livers[J].World JGastroenterol, 2014, 20 (26) :8681-8690.

[34]PENG WX, REN QX, LI X, et al.Role of blood concentration monitoring on voriconazole therapy for patients with liver failure[J].China Pharmacy, 2016, 27 (2) :267-268. (in Chinese) 彭文绣, 任秋霞, 李璇, 等.血药浓度监测在肝衰竭患者应用伏立康唑治疗肺部感染中的作用[J].中国药房, 2016, 27 (2) :267-268.

[35]TAN K, BRAYSHAW N, TOMASZEWSKI K, et al.Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities[J].J Clin Pharmacol, 2006, 46 (2) :235-243.

[36]ROUTY B, LE CE, DEROSA L, et al.Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors[J].Science, 2018, 359 (6371) :91-97.

[37]SHI M, ZHANG Z, XU R, et al.Human mesenchymal stem cell transfusion is safe and improves liver function in acute-on-chronic liver failure patients[J].Stem Cells Transl Med, 2012, 1 (10) :725-731.

[38]LIN BL, CHEN JF, QIU WH, et al.Allogeneic bone marrow-derived mesenchymal stromal cells for hepatitis B virus-related acute-on-chronic liver failure:A randomized controlled trial[J].Hepatology, 2017, 66 (1) :209-219.

施引文献

资源附件(0)

访问统计